1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI) (part of NIH). This NOFO specifically solicits SBIR grant applications from small business concerns to support later-stage research and development (Phase IIB) for projects previously funded under SBIR or STTR Phase II awards from any federal agency.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44-Clinical Trial Optional) | UC Irvine Chao Family Comprehensive Cancer Center SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44-Clinical Trial Optional) This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.
The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services.
Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period.
Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required. $4M total (Phase IIB, budget waiver topics) / 3 years Please refer to the announcement link for details.
LOI Due : Jul 05, 2022 - 2:00:PM Application Due : Aug 05, 2022 - 2:00:PM National Institutes of Health (NIH)
According to the current listing, eligibility includes: Only United States small business concerns (SBCs) that have previously received an NIH SBIR or STTR Phase II award are eligible. Only one NIH Phase IIB Strategic Breakthrough award is allowed per project. Confirm the full requirements in the official notice before applying.
NCI SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) is funded by National Cancer Institute (NCI) (part of NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI SBIR/STTR Omnibus Grant Solicitations is sponsored by National Cancer Institute (NCI) (part of NIH). The NCI offers SBIR and STTR grant opportunities for small businesses engaged in research and development within the mission of the National Institutes of Health. NCI's research areas of interest include therapeutics, in vitro and in vivo diagnostics, imaging technologies, devices for cancer therapy, tools for cancer biology research, technologies and agents for cancer prevention, technologies for cancer control, and digital health.
NIH SBIR/STTR Omnibus Grant Solicitations (NCI) is a grant program from the National Cancer Institute, part of the National Institutes of Health, that funds investigator-initiated small business innovation research across a broad spectrum of health and cancer research topic areas. The program encompassed both Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms through Phase I (R43/R41) and Phase II (R44/R42) awards, with options for both clinical trial and non-clinical trial research. Eligible applicants are U.S. small business concerns with research capabilities and technological expertise relevant to NIH's mission, including those majority-owned by venture capital operating companies, hedge funds, or private equity firms. Note that the legislative authority for the SBIR/STTR programs expired on October 1, 2025, and NIH currently has no active solicitations.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read article